Enzymatica AB (publ) (ENZY.ST)
SEK 3.4
(0.0%)
SEK 3.4
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.73 Million SEK | 162.51% |
| 2022 | -28.37 Million SEK | 2.22% |
| 2021 | -29.01 Million SEK | -203.95% |
| 2020 | -9.54 Million SEK | 59.14% |
| 2019 | -23.36 Million SEK | 64.33% |
| 2018 | -65.51 Million SEK | -2402.64% |
| 2017 | -2.61 Million SEK | 90.84% |
| 2016 | -28.59 Million SEK | -1094.89% |
| 2015 | 2.87 Million SEK | 107.58% |
| 2014 | -37.92 Million SEK | -794.76% |
| 2013 | -4.23 Million SEK | 56.09% |
| 2012 | -9.65 Million SEK | -455.61% |
| 2011 | -1.73 Million SEK | 0.0% |
| 2009 | 1.89 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 18.98 Million SEK | 1652.54% |
| 2024 Q1 | 1.08 Million SEK | -93.89% |
| 2023 Q2 | -6.46 Million SEK | 59.45% |
| 2023 Q1 | -15.95 Million SEK | 43.77% |
| 2023 FY | 17.73 Million SEK | 162.51% |
| 2023 Q4 | 17.73 Million SEK | 40.49% |
| 2023 Q3 | 12.62 Million SEK | 295.16% |
| 2022 Q4 | -28.37 Million SEK | 63.7% |
| 2022 Q1 | -17.65 Million SEK | 39.18% |
| 2022 FY | -28.37 Million SEK | 2.22% |
| 2022 Q3 | -78.16 Million SEK | -2672.79% |
| 2022 Q2 | -2.81 Million SEK | 84.03% |
| 2021 FY | -29.01 Million SEK | -203.95% |
| 2021 Q4 | -29.01 Million SEK | 21.94% |
| 2021 Q2 | -51.46 Million SEK | -637.34% |
| 2021 Q1 | -6.98 Million SEK | 26.89% |
| 2021 Q3 | -37.17 Million SEK | 27.77% |
| 2020 Q2 | -18.42 Million SEK | -1.45% |
| 2020 Q3 | -18.8 Million SEK | -2.07% |
| 2020 Q4 | -9.54 Million SEK | 49.24% |
| 2020 FY | -9.54 Million SEK | 59.14% |
| 2020 Q1 | -18.16 Million SEK | 22.27% |
| 2019 FY | -23.36 Million SEK | 64.33% |
| 2019 Q1 | -47.63 Million SEK | 27.3% |
| 2019 Q2 | -35.13 Million SEK | 26.24% |
| 2019 Q3 | -25.66 Million SEK | 26.96% |
| 2019 Q4 | -23.36 Million SEK | 8.94% |
| 2018 Q1 | -1.13 Million SEK | 56.61% |
| 2018 FY | -65.51 Million SEK | -2402.64% |
| 2018 Q3 | 28.14 Million SEK | 77.35% |
| 2018 Q2 | 15.87 Million SEK | 1497.1% |
| 2018 Q4 | -65.51 Million SEK | -332.77% |
| 2017 Q3 | -1.71 Million SEK | 82.96% |
| 2017 Q1 | -24.3 Million SEK | 15.0% |
| 2017 Q4 | -2.61 Million SEK | -52.3% |
| 2017 FY | -2.61 Million SEK | 90.84% |
| 2017 Q2 | -10.08 Million SEK | 58.49% |
| 2016 Q4 | -28.59 Million SEK | 35.16% |
| 2016 FY | -28.59 Million SEK | -1094.89% |
| 2016 Q2 | -15.42 Million SEK | -223.9% |
| 2016 Q3 | -44.09 Million SEK | -185.81% |
| 2016 Q1 | 12.45 Million SEK | 333.3% |
| 2015 Q3 | -9.67 Million SEK | 58.72% |
| 2015 Q2 | -23.43 Million SEK | 26.38% |
| 2015 Q4 | 2.87 Million SEK | 129.7% |
| 2015 Q1 | -31.83 Million SEK | 16.04% |
| 2015 FY | 2.87 Million SEK | 107.58% |
| 2014 Q2 | -66.17 Million SEK | -48404.38% |
| 2014 Q4 | -37.92 Million SEK | 27.9% |
| 2014 Q3 | -52.59 Million SEK | 20.52% |
| 2014 FY | -37.92 Million SEK | -794.76% |
| 2014 Q1 | 137 Thousand SEK | 103.23% |
| 2013 Q4 | -4.23 Million SEK | 63.99% |
| 2013 Q3 | -11.77 Million SEK | -1855.15% |
| 2013 FY | -4.23 Million SEK | 56.09% |
| 2013 Q1 | -6.55 Million SEK | 32.13% |
| 2013 Q2 | -602 Thousand SEK | 90.81% |
| 2012 Q2 | -8.49 Million SEK | -3259.48% |
| 2012 Q3 | -11.94 Million SEK | -40.53% |
| 2012 Q1 | -253.01 Thousand SEK | 0.0% |
| 2012 Q4 | -9.65 Million SEK | 19.2% |
| 2012 FY | -9.65 Million SEK | -455.61% |
| 2011 FY | -1.73 Million SEK | 0.0% |
| 2011 Q3 | -2.29 Million SEK | 44.81% |
| 2011 Q2 | -4.15 Million SEK | 0.0% |
| 2009 FY | 1.89 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 192.169% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 160.952% |
| BioGaia AB (publ) | -1.53 Billion SEK | 101.155% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 410.25% |
| Gabather AB (publ) | -1.11 Million SEK | 1690.762% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | -0.294% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 131.776% |
| Nanexa AB (publ) | -61.13 Million SEK | 129.012% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 215.905% |
| ODI Pharma AB | -2.63 Million SEK | 772.389% |
| Orexo AB (publ) | 302.8 Million SEK | 94.142% |
| Probi AB (publ) | -275.85 Million SEK | 106.43% |
| Swedencare AB (publ) | 1.42 Billion SEK | 98.752% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 99.909% |
| Toleranzia AB | -17.45 Million SEK | 201.621% |
| Vivesto AB | -1.29 Million SEK | 1465.435% |